According to Zhitong Finance APP, keros therapeutics announced today (December 4) the signing of an exclusive global development and commercialization license agreement with takeda pharmaceutical (TAK.US) to advance the development of elritercept. Elritercept is currently undergoing two phase 2 clinical trials, one for patients with very low-risk, low-risk, or medium-risk myelodysplastic syndromes (MDS), and another for patients with myelofibrosis (MF). In addition, a phase 3 clinical trial named RENEW will soon begin patient recruitment to study the efficacy of elritercept in adult patients with very low-risk, low-risk, or medium-risk MDS who are dependent on transfusions.

Under the terms of the agreement, takeda will receive exclusive rights for further global development, manufacturing, and commercialization of elritercept (excluding mainland china, Hong Kong, and Macau). From the effective date of the agreement, takeda will be responsible for all development, manufacturing, and commercialization work related to elritercept. According to the agreement, keros will receive a $0.2 billion upfront payment and is eligible for over $1.1 billion in development, regulatory, and commercial milestone payments.